Medical diagnostics firm Ellume gets German backing for TB testing

On January 9, 2019

Brisbane medical diagnostics company Ellume has received a $US15 million ($21m) investment from German biotech Qiagen as part of a broader strategic partnership between the two companies to detect tuberculosis.

Ellume announces another global partnership – this time with QIAGEN on the detection of tuberculosis

On January 8, 2019

Highlights Australia’s Ellume Limited has partnered with QIAGEN N.V. to bring the next generation of latent TB testing to low-resource, high-burden countries The deal includes the licensing of Ellume technologies and a USD $15M minority investment by QIAGEN in Ellume Limited This announcement builds on the recent announcement of a global partnership with GlaxoSmithKline announced […]

Ellume spreads global wings with GSK deal

On December 11, 2018

Brisbane medical diagnostics company Ellume has signed a significant deal with pharmaceutical giant GSK for digital consumer products, ahead of a potential market listing. Ellume founder and managing directory Sean Parsons said the global deal was the biggest of its kind in Australia.